Funding Partnerships Recent Gates Foundation grant extension supporting tuberculosis and malaria research creates a collaboration window with public funders and NGOs; leverage this momentum to pursue co-development agreements, grant-funded programs, or milestone-driven partnerships that expand AN2’s infectious disease pipeline.

Near-Term Catalysts Active Phase II programs across hematologic, infectious disease, and oncology indications with upcoming trial activity offer partnering opportunities for co-development, licensing, or in-licensing of epetraborole and other boron-based assets as accelerants for a partner’s portfolio.

Platform Differentiator A boron chemistry platform enables novel small-molecule therapies, presenting a compelling value proposition for pharma collaborators seeking differentiated discovery capabilities, platform licensing, or sponsored research partnerships across oncology, bone disorders, and infectious diseases.

Strategic Financing New financing arrangements, including at-the-market sales facilities, signal readiness to fund collaborative programs and joint clinical ventures; approach potential investors or corporate partners to secure funding for co-development deals and expansion of trials.

Bay Area Access Headquartered in Menlo Park with proximity to a dense biotech ecosystem, AN2 has access to potential collaboration partners, academic institutes, contract research organizations, and venture activity to accelerate deals, clinical trial networks, and joint development opportunities.